Zobrazeno 1 - 10
of 60
pro vyhledávání: '"RM Romero Jiménez"'
Autor:
Estela García-Martín, RM Romero-Jiménez, Ofelia Baniandrés-Rodríguez, Vicente Escudero-Vilaplana, Juana Benedí-González, Paloma Morales de los Ríos Luna, Ana Herranz-Alonso, María Sanjurjo-Sáez
Publikováno v:
European Journal of Hospital Pharmacy. :ejhpharm-2022
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35bb671c40480cfa987532a705b26440
https://doi.org/10.1136/ejhpharm-2022-003594
https://doi.org/10.1136/ejhpharm-2022-003594
Autor:
Irene Bretón-Lesmes, Almudena Ribed, Miguel Camblor-Álvarez, Pilar García-Peris, Cristina Velasco-Gimeno, M. Luisa Carrascal-Fabian, Isabel Higuera-Pulgar, RM Romero-Jiménez, Cristina Cuerda-Compes
Publikováno v:
Endocrinología, Diabetes y Nutrición. 66:472-479
Resumen Antecedentes y objetivo El tratamiento con antineoplasicos orales tipo inhibidores de tirosina quinasa (ITK) es novedoso, y por ello se conoce poco sobre como afectan al estado nutricional (EN), la ingesta dietetica, la calidad de vida, y su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ebfd0eff494e8e90bdeaee917d925c7
https://doi.org/10.1016/j.endinu.2019.03.017
https://doi.org/10.1016/j.endinu.2019.03.017
Autor:
M. Luisa Carrascal-Fabian, Irene Bretón-Lesmes, Almudena Ribed, Cristina Velasco-Gimeno, Isabel Higuera-Pulgar, Miguel Camblor-Álvarez, Cristina Cuerda-Compes, Pilar García-Peris, RM Romero-Jiménez
Publikováno v:
Endocrinología, Diabetes y Nutrición (English ed.). 66:472-479
BACKGROUND AND OBJECTIVE Treatment with oral antineoplastic agents known as tyrosine kinase inhibitors (TKIs) is new and, thus, little is known about their impact on nutritional status (NS), dietary intake, quality of life, and survival. The aim of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbff6f55f5964bf11e309339179d5b70
https://doi.org/10.1016/j.endien.2019.03.009
https://doi.org/10.1016/j.endien.2019.03.009
Autor:
RM Romero Jiménez, ME Lobato Matilla, S García Sánchez, M Sanjurjo Sáez, Á Narrillos Moraza, A Herranz Alonso, A. Ais Larisgoitia, Alejandra Melgarejo-Ortuño, E Chamorro de Vega
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Patients with immune mediated inflammatory diseases (IMID) have complex treatment. This is due to biological treatments, other chronic treatments, such as immunosuppressors, and the high load of treatments. Aim and objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1505c56d60c5b683519f0bf928c2b5dc
https://doi.org/10.1136/ejhpharm-2021-eahpconf.161
https://doi.org/10.1136/ejhpharm-2021-eahpconf.161
Autor:
FJ García-Moreno, Roberto Collado-Borrell, María Olmedo, Maricela Valerio, Elena Lobato-Matilla, Beatriz Somoza-Fernandez, Ana Herranz, Juan Carlos Lopez-Bernaldo-de-Quirós, Teresa Aldámiz-Echevarría, Silvia Manrique-Rodríguez, Emilio Bouza, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, RM Romero-Jiménez, Marina Machado, Paula Ruiz-Briones, Patricia Muñoz, Cecilia M. Fernández-Llamazares, Rafael Correa-Rocha, Milagros Sancho-Gonzalez, José Luis Revuelta-Herrero, Camino Sarobe-González, Alvaro Gimenez-Manzorro, CG Rodriguez-Gonzalez, Esther Chamorro-de-Vega, María Sanjurjo
Publikováno v:
Expert Review of Clinical Pharmacology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c533ed6110c4c54469cd542550b561ee
Autor:
RM Romero Jiménez, María Sanjurjo-Sáez, M. N. Sánchez Fresneda, M. B. Marzal-Alfaro, Ana Herranz-Alonso, M. Mañes-Sevilla, J. Benedi Gonzalez
Publikováno v:
Journal of Healthcare Quality Research. 33:33-47
Resumen Introduccion El analisis modal de fallos y efectos (AMFE) se ha utilizado como una herramienta en la gestion de los riesgos y la planificacion de la calidad. El objetivo de este estudio es identificar de forma sistematica todas las debilidade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88f83459bc9512c68d7b7cd03421afbb
https://doi.org/10.1016/j.cali.2017.12.001
https://doi.org/10.1016/j.cali.2017.12.001
Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account
Autor:
María Sanjurjo-Sáez, Roberto Collado-Borrell, Irene Iglesias-Peinado, RM Romero-Jiménez, Vicente Escudero-Vilaplana, Ana Herranz-Alonso
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 142:2319-2330
To review interactions between oral antineoplastic agents (OAAs) for the treatment of solid and hematological tumors and common food and medicinal plants.All potential interactions between OAAs, medicinal plants and food were reviewed. OAAs were cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c97cb6a6c92a238e4a9938dd75fd52a9
https://doi.org/10.1007/s00432-016-2190-8
https://doi.org/10.1007/s00432-016-2190-8
Autor:
María Sanjurjo-Sáez, RM Romero-Jiménez, Irene Iglesias-Peinado, Vicente Escudero-Vilaplana, Ana Herranz-Alonso, Almudena Ribed
Publikováno v:
Expert Opinion on Drug Safety. 15:427-435
Oral antineoplastic agents (OAA) lead to new challenges in patient education, monitoring, medication errors, drug interactions, adverse events management, and adherence. The aim is to develop a structured guide supporting pharmacist interviews and on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1945ea088f307b4dc40e091cf0819e28
https://doi.org/10.1517/14740338.2016.1150998
https://doi.org/10.1517/14740338.2016.1150998
Autor:
Almudena Ribed, María Sanjurjo-Sáez, Vicente Escudero-Vilaplana, Ana Herranz-Alonso, RM Romero-Jiménez, Carlos Codina, Irene Iglesias-Peinado
Publikováno v:
International Journal of Clinical Pharmacy. 38:280-288
Background Self-administration of oral chemotherapy regimens in the home setting leading to new challenges in the health system. Objective To develop and evaluate a comprehensive pharmaceutical care program for cancer outpatients treated with oral an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a157d3e8a25a48d3e1f3a3be2328318
https://doi.org/10.1007/s11096-015-0235-8
https://doi.org/10.1007/s11096-015-0235-8
Autor:
Irene Iglesias-Peinado, Ana Herranz-Alonso, RM Romero-Jiménez, Almudena Ribed, Roberto Collado-Borrell, María Sanjurjo-Sáez, Maite Martin-Conde, Vicente Escudero-Vilaplana, Cristina Gonzalez-Anleo
Publikováno v:
JMIR mHealth and uHealth
Background Oral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609209b44c8e811fd72c25fe779bdaa3
https://doi.org/10.2196/20480
https://doi.org/10.2196/20480